BR112023022114A2 - Composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2 - Google Patents
Composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2Info
- Publication number
- BR112023022114A2 BR112023022114A2 BR112023022114A BR112023022114A BR112023022114A2 BR 112023022114 A2 BR112023022114 A2 BR 112023022114A2 BR 112023022114 A BR112023022114 A BR 112023022114A BR 112023022114 A BR112023022114 A BR 112023022114A BR 112023022114 A2 BR112023022114 A2 BR 112023022114A2
- Authority
- BR
- Brazil
- Prior art keywords
- sglt
- inhibitor
- gpr40 agonist
- pharmaceutical compound
- same
- Prior art date
Links
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 title abstract 3
- 229940125827 GPR40 agonist Drugs 0.000 title abstract 3
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2. a presente invenção compreende uma composição farmacêutica incluindo um agonista de gpr40 e um inibidor de sglt-2, um método de preparação dos mesmos e um método de tratamento de diabetes mellitus tipo 2 e doenças semelhantes usando os mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210055992 | 2021-04-29 | ||
PCT/KR2022/006120 WO2022231357A1 (en) | 2021-04-29 | 2022-04-28 | Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023022114A2 true BR112023022114A2 (pt) | 2024-01-30 |
Family
ID=83848392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023022114A BR112023022114A2 (pt) | 2021-04-29 | 2022-04-28 | Composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP4329756A1 (pt) |
JP (1) | JP2024515137A (pt) |
KR (1) | KR20240004285A (pt) |
CN (1) | CN117241798A (pt) |
AR (1) | AR125494A1 (pt) |
AU (1) | AU2022266499A1 (pt) |
BR (1) | BR112023022114A2 (pt) |
CA (1) | CA3217858A1 (pt) |
IL (1) | IL307623A (pt) |
MX (1) | MX2023012835A (pt) |
TW (1) | TW202308620A (pt) |
UY (1) | UY39744A (pt) |
WO (1) | WO2022231357A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102007633B1 (ko) * | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
KR20240084229A (ko) * | 2022-12-06 | 2024-06-13 | 유노비아 주식회사 | 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007033002A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
US10195178B2 (en) * | 2016-04-11 | 2019-02-05 | Janssen Pharmaceutica Nv | GPR40 agonists in anti-diabetic drug combinations |
CN108430467B (zh) * | 2016-05-20 | 2021-06-22 | 晟德大药厂股份有限公司 | (r)-(+)-维拉帕米用于治疗高血糖的用途及其药学组合物 |
KR101934328B1 (ko) * | 2016-08-12 | 2019-01-02 | 주식회사 노브메타파마 | 아모디아퀸 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물 |
KR102007633B1 (ko) * | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
-
2022
- 2022-04-28 CN CN202280031057.0A patent/CN117241798A/zh active Pending
- 2022-04-28 CA CA3217858A patent/CA3217858A1/en active Pending
- 2022-04-28 KR KR1020237034149A patent/KR20240004285A/ko unknown
- 2022-04-28 UY UY0001039744A patent/UY39744A/es unknown
- 2022-04-28 IL IL307623A patent/IL307623A/en unknown
- 2022-04-28 TW TW111116273A patent/TW202308620A/zh unknown
- 2022-04-28 BR BR112023022114A patent/BR112023022114A2/pt unknown
- 2022-04-28 JP JP2023565557A patent/JP2024515137A/ja active Pending
- 2022-04-28 AU AU2022266499A patent/AU2022266499A1/en active Pending
- 2022-04-28 MX MX2023012835A patent/MX2023012835A/es unknown
- 2022-04-28 EP EP22796189.3A patent/EP4329756A1/en active Pending
- 2022-04-28 WO PCT/KR2022/006120 patent/WO2022231357A1/en active Application Filing
- 2022-04-29 AR ARP220101132A patent/AR125494A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20240004285A (ko) | 2024-01-11 |
MX2023012835A (es) | 2023-11-08 |
WO2022231357A1 (en) | 2022-11-03 |
IL307623A (en) | 2023-12-01 |
JP2024515137A (ja) | 2024-04-04 |
UY39744A (es) | 2022-11-30 |
AU2022266499A1 (en) | 2023-11-09 |
AR125494A1 (es) | 2023-07-19 |
CA3217858A1 (en) | 2022-11-03 |
CN117241798A (zh) | 2023-12-15 |
TW202308620A (zh) | 2023-03-01 |
EP4329756A1 (en) | 2024-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023022114A2 (pt) | Composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2 | |
BR112021020335A2 (pt) | Agonistas glp-1r e usos dos mesmos | |
CY1123260T1 (el) | Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου | |
BR112021022624A2 (pt) | Compostos para o tratamento da doença de huntington | |
UY38999A (es) | Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos | |
BR112021022457A2 (pt) | Inibidores de fgfr e métodos de uso dos mesmos | |
BRPI0511703B8 (pt) | composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição | |
CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
CL2012001722A1 (es) | Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes. | |
BRPI0713755A8 (pt) | composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo | |
BR112021017583A2 (pt) | Compostos, composições e métodos para o tratamento de doença | |
BR0010555A (pt) | Inibidores de neuraminidases | |
ECSP066653A (es) | Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad | |
EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
BR112022021381A2 (pt) | Compostos para o tratamento de sars | |
BR112022008786A2 (pt) | Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose | |
BR112017021529A2 (pt) | composto, composição, método para controlar uma praga e semente tratada | |
BRPI0514868A (pt) | composto, composição farmacêutica, uso de um composto, métodos para produzir um efeito inibidor de hdac em um animal de sangue quente, para tratar ou prevenir cáncer em um animal de sangue quente, e para tratar doenças, e, processo para preparar um composto | |
CL2021002205A1 (es) | Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos | |
BR112021018924A2 (pt) | Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento | |
BR112021023927A2 (pt) | Composto, e, composição farmacêutica | |
BR112021024325A2 (pt) | Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
BR112022020147A2 (pt) | Compostos para tratar a doença de huntington | |
BR112021024300A2 (pt) | Formas de sais cristalinas de um inibidor de quinase | |
CL2021002397A1 (es) | Derivados de insulina sensibles a la glucosa |